February 9, 2017 / 12:58 PM / 6 months ago

BRIEF-Viking Therapeutics announces initial results from in vivo proof-of-concept study of VK2809

Feb 9 (Reuters) - Viking Therapeutics Inc

* Viking Therapeutics announces initial results from in vivo proof-of-concept study of VK2809 in glycogen storage disease IA (GSD IA)

* Viking Therapeutics - data demonstrated treatment with VK2809 led to statistically significant reductions in key metabolic markers of GSD IA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below